Galapagos announces leadership changes amid planned company split
Ella Day | April 22, 2025 | Appointment | Analytical & Laboratory Services, Research and Development | CEO Appointment, Corporate, Galapagos, cell therapy
Galapagos NV has announced key leadership changes as it prepares to separate into two independent entities. Henry Gosebruch has been appointed founding CEO of the newly created subsidiary, currently named SpinCo. The subsidiary, which will operate independently following the split, is funded by Galapagos.
Gosebruch joins SpinCo with extensive experience in business development and mergers and acquisitions. He most recently served as CEO of Neumora and previously held senior positions at AbbVie and J.P. Morgan.
“We look forward to working with him as he pursues transactions with the potential to create significant value for all shareholders,” commented Mr Andrew Dickinson, member of Galapagos’ board of directors.
The company also confirmed that current CEO and chair Dr Paul Stoffels will step down as CEO upon the appointment of a successor, anticipated within the next 12 months. Stoffels intends to continue as chair of the board, subject to reappointment at the 2026 annual general meeting.
This leadership transition comes as Galapagos moves to focus its operations on cell therapy, with clinical programmes underway in haematological and solid tumours. SpinCo will pursue development opportunities in other areas, aiming to build a portfolio of medicines with established proof-of-concept.
The board of directors has begun the search for a new CEO to lead Galapagos through its next phase following the separation.
Ella Day
22/4/25
Related Content
Major breakthrough in T-cell receptor therapy manufacturing
For the first time, researchers at the University of Chicago in the US have successfully …
Eyestem secures $10m to advance cell therapy for advanced eye disease
Indian cell therapy company, Eyestem Research, has raised $10m in a funding round to support …
Sartorius Stedim Biotech partners with Nanotein Technologies to develop cell therapy manufacturing
Sartorius Stedim Biotech has partnered with Nanotein Technologies to expand access to immune cell activation …
